Immune Response BioPharma

I invested in a company called Immune Response Corporation (IMNR) many years ago after learning that my sister and a close friend had both been diagnosed with Rheumatoid arthritis. Immune Response was started in 1986 by Kevin Kimberlin and Jonas Salk the inventor of the Polio vaccine. The company was originally formed in response to the Aids epidemic and later branched out into other research such as rheumatoid arthritis. The company's main focus was on their Aids vaccine called REMUNE and IR103 which they claimed stabilized CD4+ Cell Counts In Drug-Naive HIV patients. In early 2007 the company began trails of a new drug called NeuroVax(TM) for Treatment of Multiple Sclerosis. The company invested thousands of hours of research along with millions of dollars in hopes of bringing a product to market. The company was first met on Wall Street with great enthusiasm with its connection to the renowned Joans Salk. The company entered into a partnership agreement with Pfizer and was developing the aids drug with a unit of Pfizer called Agouron Pharmaceuticals. The company's spokesperson Kathy Lane gave regular updates on the progress of the companies research and investors and sufferers of the various diseases they were researching had great hope.

Gradually hope and the stock price began to fall as the companies research trails continued to return failing results. In July 2001 shares for the stock were cut in half after Pfizer announced they were terminating a partnership to develop Remune's AIDS vaccine. Basically, observers noted that the companies research trails had been so poorly designed and administered that even what little positive results they achieved could not be trusted by the scientific community. The companies shares plunged as investors and employees of the company cut their losses and moved on.

In attempts to stay on the NASDAX the company reversed stock prices twice and changed their name to Orchestra Therapeutics (OCHT) in hopes of luring in more investors to stay afloat. The companies co-founder Kevin Kimberlin through Spencer Trask began giving operating money to the company in return for ownership of the companies intellectual property rights until the company finally filed Chapter 7.

A new company then emerged called Immune Response Biopharma led by David Buswell. This company claims that the research and intellectual property rights of the stock holders and Kevin Kimberlin were abandoned and that they have now claimed legal ownership. Immune Response Biopharma is seeking to issue an IPO using the Immune/Orchestra research. A spokesperson for Immune Response Biopharma said that what they are attempting to market and develop was essentially left in the trash.